The potential value of microRNA-145 for predicting prognosis in patients with ovarian cancer

Chen, Zhe; Xiao, Zelan; Zeng, Siheng; Yan, Zhiqiang

doi:10.1097/md.0000000000026922

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differentially expressed miRNA may be used as the indicator of early diagnosis, molecular typing and prognosis, including ovarian cancer. [5–7] microRNA (miR-126), originally identified as an endothelial-specific miRNA playing an essential role in angiogenesis and vascular integrity, [8,9] it has been shown to function as a critical tumor suppressor in various types of solid tumors. [10–13]…”

Section: Introductionmentioning

confidence: 99%

“…Differentially expressed miRNA may be used as the indicator of early diagnosis, molecular typing and prognosis, including ovarian cancer. [5][6][7] microRNA (miR-126), originally identified as an endothelial-specific miRNA playing an essential role in angiogenesis and vascular integrity, [8,9] it has been shown to function as a critical tumor suppressor in various types of solid tumors. [10][11][12][13] Overexpressed miR-126 can inhibit drug resistance cell proliferation and promote apoptosis of drug resistance cell, and invasion of cancer cells in various types of solid tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

et al. 2023

View full text Add to dashboard Cite

Background: Ovarian cancer is the leading cause of gynecological cancer related death in females worldwide. Our previous study demonstrated that decreased expression of microRNA (miR-126) promoted ovarian cancer angiogenesis and invasion by targeting VEGF-A. This study aimed to evaluate the clinical validity of miR-126 as a prognostic marker for epithelial ovarian cancer (EOC).Patient concerns: The patients with EOC ranged in age from 27 to 79 years, with a mean age of 57 years.Diagnosis: All patients had never had chemotherapy or biotherapy, and the diagnoses were confirmed pathologically in all cases Methods: MiR-126 levels in EOC tissue and normal ovaries were determined by qRT-PCR. Its prognostic value was analyzed using the Cox proportional hazards regression model. Survival curves were drawn using the Kaplan-Meier method.Results: In this study, we found that compared to normal tissues, miR-126 expression was lower in EOC tissues, particularly in omental metastases. Though in our previous study we found that miR-126 may inhibit proliferation and invasion in EOC cell lines, but in this study patients with elevated miR-126 expression exhibited poor overall survival and relapse free survival. Multivariate Cox regression analysis showed that miRNA-126 was an independent prognostic factor for poor relapse-free survival (P = .044). Receiver operating characteristic analysis showed that the area under the curve of miR-126 was 0.806 (95% confidence interval, 0.669-0.942). Conclusion:In this study, we established miR-126 as a potential independent biomarker for predicting recurrence in patients with EOC.Abbreviations: EOC = epithelial ovarian cancer, miR-126 = microRNA, OC = ovarian cancer, OS = overall survival, PFI = platinum-free interval, RFS = relapse-free survival, ROC = receiver operating characteristic.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool

Bhadra,

Sachan,

Nara

2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Ovarian cancer is one of the most aggressive and significant malignant tumor forms in the female reproductive system. It is the leading cause of death among gynecological cancers owing to its metastasis. Since its preliminary disease symptoms are lacking, it is imperative to develop early diagnostic biomarkers to aid in treatment optimization and personalization. In this vein, microRNAs, which are short sequence non-coding molecules, displayed great potential as highly specific and sensitive biomarker. miRNAs have been extensively advocated and proven to serve an instrumental part in the clinical management of cancer, especially ovarian cancer, by promoting the cancer cell progression, invasion, delayed apoptosis, epithelial-mesenchymal transition, metastasis of cancer cells, chemosensitivity and resistance and disease therapy. Here, we cover our present comprehension of the most up-to-date microRNA-based approaches to detect ovarian cancer, as well as current diagnostic and treatment strategies, the role of microRNAs as oncogenes or tumor suppressor genes, and their significance in ovarian cancer progression, prognosis, and therapy.

show abstract

The potential value of microRNA-145 for predicting prognosis in patients with ovarian cancer

Cited by 2 publications

References 24 publications

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool

Contact Info

Product

Resources

About